John Monahan
Director/Board Member at SCORPIUS HOLDINGS, INC.
Net worth: 12 $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Catelani | M | 57 |
Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | 15 years |
Jeff Wolf | M | 60 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 18 years |
John Prendergast | M | 70 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA.
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 26 years |
Steven Shallcross | M | 62 | 9 years | |
William Ostrander | M | 56 | 5 years | |
Vivienne Williams | F | - |
Cellix Ltd.
Cellix Ltd. Medical SpecialtiesHealth Technology Cellix Ltd. develops microfluidic pumping solutions, consumable biochips, software, and automated solutions. It offers its solutions for applications in cell biology, microfluidics and nanofluidics, physics, chemistry, cell, and particle studies. The company was founded by Dmitry Kashanin, Vivienne Williams, Francis Odowd, and Igor Shvets in 2004 and is headquartered in Dublin, Ireland. | 20 years |
Edward Smith | M | 48 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 15 years |
Jeffrey Kraws | M | 59 | 18 years | |
Emily Gottschalk | F | 63 | 5 years | |
Arnold Baskies | M | 74 | 8 years | |
Dmitry Kashanin | M | - |
Cellix Ltd.
Cellix Ltd. Medical SpecialtiesHealth Technology Cellix Ltd. develops microfluidic pumping solutions, consumable biochips, software, and automated solutions. It offers its solutions for applications in cell biology, microfluidics and nanofluidics, physics, chemistry, cell, and particle studies. The company was founded by Dmitry Kashanin, Vivienne Williams, Francis Odowd, and Igor Shvets in 2004 and is headquartered in Dublin, Ireland. | 20 years |
Paul Tebbey | M | - |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 3 years |
Igor Shvets | M | - |
Cellix Ltd.
Cellix Ltd. Medical SpecialtiesHealth Technology Cellix Ltd. develops microfluidic pumping solutions, consumable biochips, software, and automated solutions. It offers its solutions for applications in cell biology, microfluidics and nanofluidics, physics, chemistry, cell, and particle studies. The company was founded by Dmitry Kashanin, Vivienne Williams, Francis Odowd, and Igor Shvets in 2004 and is headquartered in Dublin, Ireland. | 20 years |
Yuichi Iwaki | M | 74 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | 30 years |
Richard Fernandes | M | - |
Luxcel Biosciences Ltd.
Luxcel Biosciences Ltd. Medical SpecialtiesHealth Technology Luxcel Biosciences Ltd. develops, manufactures, and distributes optical fluorescence test solutions for application in the pharmaceutical and food safety industries. It offers MitoXpress Xtra oxygen consumption assay, MitoXpress stress test, MitoXpress FAO assay, pH-Xtra Glycolysis assay, and pH-Xtra Glycolysis stress test. The company was founded by Richard Fernandes and Dmitri Papkovsky in 2002 and is headquartered in Cork, Ireland. | 22 years |
David Waldman | M | - | - | |
Jane G. Farrar | M | - |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
Paul Kenna | M | - |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
George Peoples | M | - | - | |
Ramon Alemany | M | - | 1 years | |
T. J. Swope | M | - | - | |
Manel Cascalló | M | - | 2 years | |
Ena Prossner | M | 58 |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
Michael Kaleko | M | - | 12 years | |
Vince Wacher | M | - | - | |
Alan Keith Boyd | M | 70 |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
Dermot Kelleher | M | 68 |
Cellix Ltd.
Cellix Ltd. Medical SpecialtiesHealth Technology Cellix Ltd. develops microfluidic pumping solutions, consumable biochips, software, and automated solutions. It offers its solutions for applications in cell biology, microfluidics and nanofluidics, physics, chemistry, cell, and particle studies. The company was founded by Dmitry Kashanin, Vivienne Williams, Francis Odowd, and Igor Shvets in 2004 and is headquartered in Dublin, Ireland. | - |
Peter FitzGerald | M | - |
Cellix Ltd.
Cellix Ltd. Medical SpecialtiesHealth Technology Cellix Ltd. develops microfluidic pumping solutions, consumable biochips, software, and automated solutions. It offers its solutions for applications in cell biology, microfluidics and nanofluidics, physics, chemistry, cell, and particle studies. The company was founded by Dmitry Kashanin, Vivienne Williams, Francis Odowd, and Igor Shvets in 2004 and is headquartered in Dublin, Ireland. | - |
Joey Mason | M | - |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | - |
Elizabeth Posillico | M | - |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 22 years |
Robert Demorest | M | 78 |
Luxcel Biosciences Ltd.
Luxcel Biosciences Ltd. Medical SpecialtiesHealth Technology Luxcel Biosciences Ltd. develops, manufactures, and distributes optical fluorescence test solutions for application in the pharmaceutical and food safety industries. It offers MitoXpress Xtra oxygen consumption assay, MitoXpress stress test, MitoXpress FAO assay, pH-Xtra Glycolysis assay, and pH-Xtra Glycolysis stress test. The company was founded by Richard Fernandes and Dmitri Papkovsky in 2002 and is headquartered in Cork, Ireland. | - |
Dimitri Papkovsky | M | - |
Luxcel Biosciences Ltd.
Luxcel Biosciences Ltd. Medical SpecialtiesHealth Technology Luxcel Biosciences Ltd. develops, manufactures, and distributes optical fluorescence test solutions for application in the pharmaceutical and food safety industries. It offers MitoXpress Xtra oxygen consumption assay, MitoXpress stress test, MitoXpress FAO assay, pH-Xtra Glycolysis assay, and pH-Xtra Glycolysis stress test. The company was founded by Richard Fernandes and Dmitri Papkovsky in 2002 and is headquartered in Cork, Ireland. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Andrew A. Sauter | M | 57 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | 10 years |
Bruce F. Johnson | M | 81 | 6 years | |
Melissa Price | M | 49 | 3 years | |
Robert James Jakobs | M | 69 | - | |
Ann A. Rosar | F | 72 | 4 years | |
Jeff T. Hutchins | M | 65 | 3 years | |
Louis C. Bock | M | 59 | 3 years | |
Robert Berman | M | 61 | 5 years | |
David Warren Carter | M | 84 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 6 years |
Vincent I. Perrone | M | - | - | |
Jennifer Lynn Harris | M | 58 | - | |
Dale Fox | M | 56 | 3 years | |
Paul M. Belsky | M | 67 | 7 years | |
Sara M. Hall | F | - |
Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | - |
Michael Kharitonov | M | 60 | 7 years | |
Kathy Ordoñez | F | 73 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | 15 years |
Robert Burke | M | - |
University College Dublin
| 6 years |
Matthew E. Czajkowski | M | 73 | 2 years | |
Scott Tarriff | M | 64 | 8 years | |
Richard H. Williams | M | 87 | 1 years | |
Kenneth Chahine | M | 59 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | 11 years |
Kirk William Johnson | M | 64 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | 5 years |
Timothy J. Creech | M | 63 | 1 years | |
Amit Kumar | M | 59 |
Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | - |
David Cavalier | M | 54 | 3 years | |
Tom Paulson | M | 77 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | 10 years |
Henry P. Herms | M | 78 | 16 years | |
Mary Christina Thomson | F | 53 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | 9 years |
Robert J. Roy | M | - |
McMaster University
| 4 years |
Kee Lam Chua | M | 82 |
McMaster University
| 3 years |
Bruce Jackson | M | - |
McMaster University
| 2 years |
Brian M. Smith | M | - |
McMaster University
| 4 years |
Roberta Bondar | M | - |
McMaster University
| 3 years |
Jim MacDonald | M | - |
McMaster University
| 2 years |
Ka Hing Leung | M | 68 |
McMaster University
| 4 years |
Ming Foo Lee | M | 70 |
McMaster University
| 4 years |
Barry Wohl | M | 71 |
McMaster University
| 4 years |
Tze Kin Wong | M | 70 |
McMaster University
| 4 years |
Paul Wojdak | M | - |
McMaster University
| 4 years |
Chun Hung Tam | M | 73 |
McMaster University
| 4 years |
Dennis Grimm | M | 72 |
McMaster University
| 2 years |
Yan Leung Cheung | M | 73 |
McMaster University
| 4 years |
Yuk-Yee Yeung | F | 69 |
McMaster University
| 4 years |
Robert Taylor | M | 77 |
McMaster University
| 2 years |
Zakaria bin Ahmad | M | 77 |
McMaster University
| 1 years |
Raymond J. Seabrook | M | 73 |
McMaster University
| 4 years |
Gary Kain | M | - |
McMaster University
| 2 years |
Fred Grigsby | M | - |
McMaster University
| 2 years |
Wilfred Gobert | M | 76 |
McMaster University
| 2 years |
Edward G. Frackowiak | M | 69 |
McMaster University
| 4 years |
Allan Nelson Meyer | M | - |
McMaster University
| 4 years |
Douglas M. Carruthers | M | - |
McMaster University
| 4 years |
Marvin Wolff | M | - |
McMaster University
| 4 years |
Michael Marchand | M | - |
McMaster University
| 3 years |
John Schindler | M | - |
McMaster University
| 3 years |
Miles Nagamatsu | M | 67 |
McMaster University
| 4 years |
Douglas C. Lord | M | 73 |
McMaster University
| 4 years |
Robert Morris Bryniak | M | 73 |
McMaster University
| 4 years |
Alan Torrie | M | 73 |
McMaster University
| 4 years |
John E. Barker | M | 76 |
McMaster University
| 4 years |
Anthony Giovinazzo | M | 67 |
McMaster University
| 4 years |
Douglas Underhill | M | - |
McMaster University
| 3 years |
Graham Turner | M | - |
McMaster University
| 3 years |
Thomas J. Irvine | M | 75 |
McMaster University
| 4 years |
Robert J. Mepham | M | - |
McMaster University
| 4 years |
Bill Anderson | M | - |
McMaster University
| 4 years |
Anthony John Murphy | M | 73 |
University College Dublin
| 4 years |
Richard J. Bruno | M | - |
McMaster University
| 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 46 | 46.00% |
Canada | 39 | 39.00% |
Ireland | 15 | 15.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Monahan
- Personal Network